IDL Diagnostics AB (OSTO:IDLDX) ROCE %: 3.32% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IDLDX IDL Diagnostics AB OSTO:IDLDX
55 GF Score
Price kr0.42
GF Value kr0.54
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is IDL Diagnostics AB ROCE %?

IDL Diagnostics AB OSTO:IDLDX +3.69% 55 ROCE % is 3.32% as of Mar. 2026. GuruFocus rates OSTO:IDLDX with a GF Score™ of 55/100 and a GF Value™ of kr0.54 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IDL Diagnostics AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.32%.

IDL Diagnostics AB  (OSTO:IDLDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IDL Diagnostics AB ROCE % Related Terms

IDL Diagnostics AB ROCE % Historical Data

* Premium members only.

The historical data trend for IDL Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDL Diagnostics AB ROCE % Chart

IDL Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.95 -26.94 -29.52 -1.61 -7.04

IDL Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.82 -59.01 -9.32 -3.39 3.32
OSTO:IDLDX
55GF Score
IDL Diagnostics AB OSTO:IDLDX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDL Diagnostics AB ROCE % Calculation

IDL Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-11.714/( ( (188.532 - 14.987) + (176.862 - 17.666) )/ 2 )
=-11.714/( (173.545+159.196)/ 2 )
=-11.714/166.3705
=-7.04 %

IDL Diagnostics AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5.296/( ( (176.862 - 17.666) + (175.828 - 15.992) )/ 2 )
=5.296/( ( 159.196 + 159.836 )/ 2 )
=5.296/159.516
=3.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.32% mean?
IDL Diagnostics AB (OSTO:IDLDX) has a ROCE % of 3.32% as of Mar. 2026.
Is IDL Diagnostics AB's ROCE % too high?
IDL Diagnostics AB's current ROCE % is 3.32%. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's ROCE % compare to TMO and DHR?
IDL Diagnostics AB's ROCE % of 3.32% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. IDL Diagnostics AB's current ROCE % is 3.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.42 — trading 21.9% below its estimated fair value. The current ROCE % is 3.32%. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current ROCE % is 3.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?

Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued. The current stock price of kr0.42 is trading 21.9% below its estimated GF Value™ of kr0.54. GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.

Key valuation signals for OSTO:IDLDX:

  • ROCE %: 3.32%
  • GF Value™: kr0.54 vs. price of kr0.42 (21.9% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDL Diagnostics AB Business Description

Address Karlsbodavagen 39, Bromma, Stockholm, SWE, 168 67
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score

Get the complete analysis for OSTO:IDLDX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.42
Price
kr0.54
GF Value